Achieve Life Sciences Inc. is a pharmaceutical company. It develops and commercializes cytisine treatment to help people battling nicotine addiction. The Company's product candidates include Custirsen, Apatorsen and OGX-225. Achieve Life Sciences Inc., formerly known as OncoGenex Pharmaceuticals Inc., is based in Bothell, United States.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-54.65M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.58 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -127.13% |
| Return on Assets (Trailing 12 Months) | -53.42% |
| Current Ratio (Most Recent Fiscal Quarter) | 10.49 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.95 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.03 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.64 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.28 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.25 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.55 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 110.03M |
| Free Float | 108.05M |
| Market Capitalization | $692.12M |
| Average Volume (Last 20 Days) | 1.26M |
| Beta (Past 60 Months) | 2.42 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 33.52% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |